- Home
- CYH vs EYPT Comparison
CYH vs EYPT Comparison
Compare CYH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | EYPT |
|---|---|---|
| Founded | 1985 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.5M | 1.5B |
| IPO Year | 1991 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CYH | EYPT |
|---|---|---|
| Price | $3.23 | $18.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $3.73 | ★ $29.60 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 10-23-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $12,644,000,000.00 | $42,339,000.00 |
| Revenue This Year | $0.04 | N/A |
| Revenue Next Year | $0.86 | N/A |
| P/E Ratio | $1.30 | ★ N/A |
| Revenue Growth | ★ 0.74 | N/A |
| 52 Week Low | $2.24 | $3.91 |
| 52 Week High | $4.47 | $19.11 |
Technical Indicators
Market Signals| Indicator | CYH | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.38 | 66.55 |
| Support Level | $3.20 | $16.52 |
| Resistance Level | $3.30 | $19.00 |
| Average True Range (ATR) | 0.13 | 1.04 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 11.18 | 74.24 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.